CIDRAP newsletters options
Subvariant patterns are in flux, with BA.5 Omicron lineages still dominant, but XBB.1.5 gaining ground.
All genomes belonged to the existing 123 Pango lineage, demonstrating no persistently dominant SARS-CoV-2 variants or new strains.
Data reveal that 60% of cancer patients still have COVID-19 symptoms for 7 months after infection, similar to the general population.
Experts fear the incident could hamper the US-China medical supply chain, including upending FDA regulatory inspections.
The man didn't have direct contact with camels, though camel racing exercises were held near his house before he fell ill.
Since Nov 1, 2022, a total of 559 cases have been reported, 18 of them fatal, for a case-fatality rate of 2.3%.
The World Organization for Animal Health notes increasing detections in mammals in recent months, which warrants close monitoring.
Conservative physicians were five times more likely than their peers to say that they would treat a hypothetical COVID-19 patient with hydroxychloroquine.
The emergence of multidrug-resistant strains of the enteric pathogen is challenging clinicians and public health officials.
Early during COVID-19, 622 more US physicians died than expected, but no excess deaths occurred after April 2021, when vaccines were broadly available.
Over the first 2 years of the pandemic, global antibiotic sales increases were linked with rises in COVID-19 cases.
Two more cases have been confirmed, raising the total to 10 cases, 7 of them fatal.
Of 1,981 COVID-positive women, 44.0% developed long COVID, of whom 87.0% reported symptoms lasting at least 2 months.
People on dialysis for kidney disease are 100 times more likely to have Staphylococcus aureus bloodstream infections than other people.
Early in COVID-19, rates of lung and breast cancer screenings among Medicare enrollees were 24% and 17%, respectively, below expected rates, rising to -14% and -4% later on.
Regular audit and feedback did not reduce antibiotic prescribing among physicians with high prescribing rates, according to a randomized controlled trial.
The more transmissible XBB.1.5 Omicron subvariant continues to gain ground in all US regions.
The Centers for Innovation in Advanced Development and Manufacturing had difficulty reliably producing larger drug product amounts.
Overall 2-dose protection against Omicron-related hospitalization or death remained above 70% for at least 6 months.
Also, Shionogi announces that the novel antibiotic cefiderocol is now available in Denmark for treating infections caused by gram-negative bacteria in patients with limited treatment options.
